PBAC ramps up biosimilar drive

The Pharmaceutical Benefits Advisory Board has recommended the PBS listing of infliximab biosimilar Inflectra for the same indications as its comparator drug, Remicade.

More controversially, it also says the biosimilar should be “a-flagged”, meaning pharmacists should be allowed to dispense Inflectra when Remicade has been prescribed.

Such a move could drive substantial savings for the PBS: recently